Kristian Reich - 08 Dec 2025 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Role: Chief Scientific Officer
Signature: /s/ Matthias Bodenstedt, Attorney-in-fact for Kristian Reich
Issuer symbol: MLTX
Transactions as of: 08 Dec 2025
Transactions value $: -$3,012,462
Form type: 4
Filing time: 10 Dec 2025, 16:29:11 UTC
Previous filing: 04 Sep 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Reich Kristian	Chief Scientific Officer	C/O MOONLAKE IMMUNOTHERAPEUTICS, DORFSTRASSE 29, ZUG, SWITZERLAND	/s/ Matthias Bodenstedt, Attorney-in-fact for Kristian Reich	10 Dec 2025	0001920553

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MLTX	Class A ordinary shares, par value $0.0001 per share	Sale	-$1.96M	-130K	-64.07%	$15.08	72.9K	08 Dec 2025	Direct	F1, F2
transaction	MLTX	Class A ordinary shares, par value $0.0001 per share	Sale	-$1.05M	-72.9K	-100%	$14.43	0	09 Dec 2025	Direct	F1
holding	MLTX	Class A ordinary shares, par value $0.0001 per share						2.97M	08 Dec 2025	See footnote.	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended, to cover tax liabilities of the Reporting Person and other expenses incurred related to the sales.
F2	The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $15.036949 to $15.101507. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3	Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.